Last reviewed · How we verify
NCT02712567
SARC021C: A Continuation Study of TH-CR-406/SARC021
trial testing Th-302 in Soft Tissue Sarcoma. No longer available.
Quick facts
| Lead sponsor | Sarcoma Alliance for Research through Collaboration |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Th-302 — full drug profile →
Conditions studied
- Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →
Sponsor
Sarcoma Alliance for Research through Collaboration — full company profile →
Who can join
Eligibility, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02712567
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Soft Tissue Sarcoma
Currently open trials in the same condition.
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
- NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
- NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
- NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting
Other Sarcoma Alliance for Research through Collaboration trials
Trials by the same sponsor.
- NCT07104331 — SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma · Phase 2 · recruiting
- NCT06942442 — A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma · Phase 2 · recruiting
- NCT04067115 — SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patien · Phase 1, PHASE2 · completed
- NCT03433183 — SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignan · Phase 2 · completed
- NCT03092323 — A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02712567 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sarcoma Alliance for Research through Collaboration
- Last refreshed: 13 October 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02712567.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing